(2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:151800

Synonyms

alpha-D-gluco-hexopyranosyl-(1->2)-[alpha-D-gluco-hexopyranosyl-(1->3)]-alpha-D-gluco-hexopyranose
Glc(a1-2)[Glc(a1-3)]a-Glc
WURCS=2.0/1,3,2/[a2122h-1a_1-5]/1-1-1/a2-b1_a3-c1

Definition

References

GlyGen:G54253UO
GlyTouCan:G54253UO

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2,5-Dihydroxy-6-(hydroxymethyl)-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model